NEXTBio Capital Management LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002038158

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 24 positions · Total reported value $229.71M · Top-10 concentration 69.0% · Updated 2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

Turnover: 38.5% · 4 new · 4 cut · 2 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -4.2% · vs SPY -6.3% · Prev Value $217.40M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.2% · vs SPY -5.4% · Latest Value $229.71M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, NEXTBio Capital Management LP disclosed 24 equity positions with a combined reported value of $229.71M. The filing implies a focused portfolio: its ten largest positions account for 69.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PTGX ($30.90M), STTK ($25.42M), CMPS ($22.09M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, NEXTBio Capital Management LP opened 4 new positions, trimmed 4 and fully exited 2, a turnover rate of 38.5% of positions. The portfolio's overlap with the prior quarter was 77% of names.

The largest new positions opened in Q3 2026 were ENTX ($8.51M), ANIX ($5.61M), VNDA ($1.99M).

Of the 2 positions fully exited versus the prior quarter, the largest were BIOA ($2.47M), ACET ($1.36M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • ENTX Entera Bio Ltd · $8.51M
  • ANIX ANIXA BIOSCIENCES · $5.61M
  • VNDA VANDA PHARMACEUTICALS INC · $1.99M
  • GLUE MONTE ROSA THERAPEUTICS INC · $1.33M

Fully Exited (vs previous quarter)

  • BIOA BIOAGE LABS INC · prev qtr: $2.47M
  • ACET ADICET BIO INC · prev qtr: $1.36M

Insider Transactions (Form 4)

Latest NEXTBio Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

NEXTBio Capital Management LP, based in Austin, TX, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 22 positions worth $217.40M in total. HoldingsHub carries 3 quarters of its filings (Q4 2025–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-136876 (status: Approved), registered 2026-07-23
  • Regulatory AUM (Form ADV): $305.21M as of 2026-07-07
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 6 private funds, of which 1 hedge funds
  • Website: nextbiocapital.com

Portfolio Structure

  • 22 positions · $217.40M reported value (Q2 2026)
  • Top 10 holdings = 77.7% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 12.4%
  • Average position size: $9.88M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 3 new, 7 added, 4 reduced, 5 exited
  • 8 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 219.33K $30.90M 13.45%
13.45%
Hold
2 3.73M $25.42M 11.07%
11.07%
Hold
3 1.78M $22.09M 9.62%
9.62%
Hold
4 131.76K $12.55M 5.46%
5.46%
Hold
5 620.93K $11.85M 5.16%
5.16%
Reduce
6 372.55K $11.82M 5.14%
5.14%
Add
7 310.23K $11.54M 5.02%
5.02%
Add
8 426.74K $11.51M 5.01%
5.01%
Hold
9 80.41K $11.09M 4.83%
4.83%
Reduce
10 312.50K $9.77M 4.25%
4.25%
Hold
11 684.48K $9.22M 4.01%
4.01%
Reduce
12 2.92M $8.51M 3.70%
3.70%
New
13 906.74K $7.30M 3.18%
3.18%
Reduce
14 1.79M $6.60M 2.87%
2.87%
Hold
15 238.36K $6.28M 2.73%
2.73%
Add
16 107.22K $6.10M 2.66%
2.66%
Hold
17 178.04K $5.70M 2.48%
2.48%
Add
18 175.40K $5.61M 2.44%
2.44%
New
19 372.86K $5.44M 2.37%
2.37%
Hold
20 52.66K $3.45M 1.50%
1.50%
Hold
21 69.55K $2.67M 1.16%
1.16%
Add
22 100.00K $1.99M 0.87%
0.87%
New
23 111.45K $1.33M 0.58%
0.58%
New
24 119.06K $983.46K 0.43%
0.43%
Hold

FAQ

What did NEXTBio Capital Management LP buy in 2026-Q3?

In its 2026-Q3 13F filing, NEXTBio Capital Management LP reported 24 equity positions worth $229.71M in aggregate; its largest disclosed positions were PTGX ($30.90M), STTK ($25.42M), CMPS ($22.09M).

How large is NEXTBio Capital Management LP's portfolio?

NEXTBio Capital Management LP reported $229.71M of long equity holdings across 24 positions as of 2026-Q3. Top-10 holdings account for 69.0% of reported value.

What is NEXTBio Capital Management LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/nextbio-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →